Release date: 2014-06-13
Myriad Genetics has patents on two genes for breast and ovarian cancer that have allowed them to monopolize the industry for breast cancer testing for many years. Although the US Supreme Court had invalidated the patents for these two genes in June last year, the company still holds the unique 1.3 million test data. This information gives Meliad a huge advantage in interpreting test results. But geneticists and patients believe that such advantages will be gradually smoothed out.
In the one year after the two gene patents were invalidated, the detection data on the mutations of the two genes BRCA1 and BRCA2 were stored in the public information database of ClinVar, and in the database for one year. The data has reached one-third of the unique data of Mirard Genes.
ClinVar now uses 5,752 data from different BRCA genes, while Meliad has 16,000 genetic data. Geneticists have been pushing data for a long time, but they have not been realized for some practical and competitive reasons. Data sharing takes time and money to promote, but such data sharing is helpful for disease detection and patient benefit.
If public data can reach the same number of data as Myriad Gene, perhaps such data sharing is easier to achieve.
Source: Bio Valley
Cheap Fried Garlic Granules,New Crop Fried Garlic Flakes,Fried Garlic Granules Bulk ,Fried Garlic Dried Garlic
Shanghai Sinospices Sourcing Ltd , https://www.garlicall.com